A 35-year-old woman with poorly controlled type 2 diabetes mellitus presents with erythema, maceration, and white plaques in her vulvovaginal region. She reports pruritus and vaginal discharge for 1 week. She denies fever or systemic symptoms. Wet mount microscopy shows pseudohyphae and budding yeast. She has had two similar episodes in the past 6 months. Which of the following is the BEST initial step in her management?

Explanation

## Clinical Context: Recurrent Vulvovaginal Candidiasis (RVVC) **Key Point:** RVVC is defined as ≥4 symptomatic episodes per year. This patient has had 2 episodes in 6 months (annualized rate ~4/year), meeting the threshold for RVVC, with a clear predisposing factor: poorly controlled diabetes mellitus. The standard of care for RVVC is **induction therapy followed by maintenance/suppressive therapy**, not topical azole alone. ## Pathophysiology of Candidiasis in Diabetes **Mnemonic:** **GLUCOSE FEEDS FUNGI** — Hyperglycemia increases: - Glucose in urine and vaginal secretions (substrate for *Candida*) - Impaired neutrophil function (reduced chemotaxis and phagocytosis) - Altered vaginal pH and microbiota - Epithelial cell adhesion of *Candida* species ## Management Algorithm for RVVC (CDC / ACOG Guidelines) ``` Confirmed RVVC (≥4 episodes/year or recurrent pattern) ↓ Induction: Oral fluconazole 150 mg every 72 hours × 3 doses ↓ Maintenance: Oral fluconazole 150 mg weekly × 6 months ↓ Address predisposing factors (optimize glycemic control, avoid irritants) ↓ Monitor for recurrence after stopping maintenance ``` ## Treatment Comparison: Acute vs. Recurrent Disease | Scenario | First-Line | Duration | Rationale | |----------|-----------|----------|-----------| | **Acute, non-recurrent** | Topical azole OR oral fluconazole 150 mg × 1 | 7 days topical; single dose oral | Cost-effective; minimal systemic exposure | | **RVVC (≥4/year)** | Oral fluconazole induction + **weekly maintenance** | 6 months maintenance | Reduces recurrence rate from ~50% to <10% (Sobel et al., NEJM 2004) | | **RVVC + uncontrolled DM** | Fluconazole induction + maintenance + **glycemic optimization** | 6 months minimum | Dual approach: treat infection AND remove predisposing factor | **High-Yield (KD Tripathi / CDC 2021 STI Guidelines):** For RVVC, the recommended regimen is: 1. **Induction:** Fluconazole 150 mg orally every 72 hours for 3 doses 2. **Maintenance:** Fluconazole 150 mg orally once weekly for 6 months Option B (fluconazole 150 mg single dose then weekly for 6 weeks) most closely represents this induction + maintenance approach among the available options, making it the best initial step for a patient with RVVC. ## Why Option C Is Insufficient Here **Clinical Pearl:** While topical clotrimazole and glycemic optimization are important adjuncts, topical azole monotherapy for 7 days is the standard for **uncomplicated, non-recurrent** vulvovaginal candidiasis. In RVVC, topical therapy alone has a high recurrence rate (~50% within 3 months) without a structured maintenance regimen. The BEST initial step must include a suppressive/maintenance oral azole strategy. ## Why Other Options Are Incorrect - **Option A (fluconazole weekly indefinitely):** Suppressive therapy is typically limited to 6–12 months, not indefinite; "indefinitely" is not evidence-based and risks azole resistance. - **Option C (clotrimazole 7 days + glycemic control):** Appropriate for a first/isolated episode, but insufficient for RVVC — does not include a maintenance regimen. - **Option D (pelvic ultrasound):** Not indicated; the diagnosis is established clinically and by wet mount. No gynecological pathology is suggested by the history. **Reference:** Sobel JD et al., *NEJM* 2004; CDC STI Treatment Guidelines 2021; KD Tripathi, *Essentials of Medical Pharmacology*, 8th ed.